What does Lily stock do?

Lily, as a health care product company, set foot on the IPO road for the first time as early as 20 15, and plans to land on the Growth Enterprise Market. After a lapse of four years, the revocation of materials ended. However, after only one year of preparation, Lily.com once again submitted an application for listing on the main board of Shanghai Stock Exchange. After experiencing a series of twists and turns in the suspension of voting, it finally obtained the IPO approval from the CSRC in June 2022.

After so many ups and downs, Lily shares, which are bent on "circling money", are also a minor celebrity. Curious, the author also wants to explore why the listing process of this enterprise is so tortuous and whether it is a good target.

I really don't know when I look at it. I was shocked at first sight. This star enterprise in Weihai, Shandong Province, has a really big problem! Products and packaging are "copied" all the way, and the top five customers are frequently fooled and changed. In addition to technical content and production difficulty, corporate reputation is really not high.

1. The Magic of Health Care Industry

The author first talks about this "least clear" industry-health care products.

The medical and health care products market in China started in 1980s, and the advertising bombing and concept speculation made indelible contributions to the industry progress and economic development.

1987, Hangzhou launched royal jelly products, which opened the curtain of China health care products market. Since 1990s, Dongguan Sun God Company, Shandong Zhu San Oral Liquid, Shenzhen Healthy Yuan (Taitai Oral Liquid) and Shanghai Giant Brain Gold have been born successively. At that time, Ma Yun was still an English teacher, Mark was still studying at Shenzhen University, and Xu Jiayin was running around the recruitment market in Shenzhen with more than 20 pages of resume.

At that time, the health care industry was far more eye-catching and beautiful than today.

During the period of 1995, the incident of Chinese soft-shelled turtle essence broke out, which uncovered the shady situation of counterfeit and shoddy products in the domestic health care products market. Affected by this, health care industry has been seriously questioned by consumers. Coupled with the country's vigorous rectification, the whole industry has experienced an obvious recession. 20 18 All-Health Event pushed the health care industry to the forefront. In 20 19, the health care industry also ushered in the strictest supervision, and the whole industry suffered a major reshuffle.

In fact, health care industry has been questioned by various problems, such as exaggerating curative effect, false propaganda, high-priced sales and so on. Even a health care product agent of a big brand ridiculed: "No blowing, no black. At present, most health care products on the market have two characteristics: one is non-toxic and the other is useless. "

However, health care products are also a magical industry, "being chased while being pitted". China is a big country selling health products. According to Euromonitor data, the market size of China's health care industry has increased from 69.5 billion yuan in 20 10 to162.7 billion yuan in 20 18, with a compound annual growth rate of about1.2%. It is estimated that by 2022, the market scale is expected to reach 2.3/kloc-0.60 billion yuan, and the compound annual growth rate from 20 18 to 2022 is about 9.2%.

It can be said that the health care products market is regarded as the fastest growing and most profitable field in China food industry.

There have been many controversies about health care products in the past, and there will be no less in the future, but the people's demand for health care products will not change much. To some extent, health care products business is to collect IQ tax, but this is not the focus of my discussion. The author wants to analyze whether Lily is a good target through the prospectus and financial report, and whether this enterprise has come to harvest the "IQ tax" of shareholders.